Sequenom's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Sequenom ( SQNM)

Q4 2011 Earnings Call

March 7, 2012 5:00 p.m. ET


Marcy Graham - Senior Director, IR

Harry Hixson - Chairman and CEO

Paul Maier - CFO

Ron Lindsay - Director and EVP

Bill Welch - SVP, Diagnostics

Dirk van den Boom - SVP, Research and Development


Nandita Koshal - Barclays Capital

David Ferreiro - Oppenheimer

Brian Weinstein - William Blair

Kevin DeGeeter - Ladenburg Thalmann

David Clair - Piper Jaffray

Jon Wood - Jefferies

Junaid Husain - Dougherty & Company

Elemer Piros - Rodman & Rodman & Renshaw

Zarak Khurshid - Wedbush Securities



Good afternoon, and welcome to the Sequenom fourth quarter and full year 2011 earnings conference call. [Operator instructions.] I would now like to turn the conference over to Marcy Graham, senior director of investor relations. Please go ahead.

Marcy Graham

Thank you operator. Welcome to the Sequenom conference call to discuss operating results for the fourth quarter and full year 2011. Joining me today is Dr. Harry Hixon, chairman and CEO; Paul Maier, CFO; Dr. Ron Lindsay, director and executive vice president of research and development; Bill Welch, senior vice president of diagnostics; and Dr. Dirk van den Boom, senior vice president of research and development, will all three join us later for the Q&A portion of our call.

This is also being broadcast live over the web, and will be available for replay through Thursday, March 15, 2012 on the investor section of our website at Before we begin, please note that this call will include a discussion of Sequenom and Sequenom CMM's current plans and intentions regarding product development and commercialization and other matters, as well as expectations regarding Sequenom's financial resources or future financial performance, statements that are not historical facts but forward-looking statements.

If you liked this article you might like

These 5 Stocks Under $10 Are Set to Soar Higher

Insider Trading Alert - KSU, TLMR And SQNM Traded By Insiders

Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment

Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment

Insider Trading Alert - SQNM, OFIX And CIEN Traded By Insiders

5 Stocks Insiders Love for 2016